For the year ending 2025-12-31, CAPR had $276,560,316 increase in cash & cash equivalents over the period. -$72,715,722 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -105,043,946 |
| Loss on disposal of fixed assets | -157,519 |
| Depreciation and amortization | 1,889,041 |
| Stock-based compensation | 16,967,799 |
| Restricted stock awards granted | 257,461 |
| Changes in lease liabilities | 715,459 |
| Non-cash interest expense on cirm liability | 3,045,725 |
| Receivables | -10,309,322 |
| Prepaid expenses and other assets | 4,093,633 |
| Accounts payable and accrued expenses | 5,983,992 |
| Deferred revenue | 0 |
| Net cash used in operating activities | -69,811,261 |
| Purchase of marketable securities | 151,392,398 |
| Proceeds from sales and maturities of marketable securities | 260,595,875 |
| Purchases of property and equipment | 2,904,461 |
| Payments for leasehold improvements | 383,539 |
| Payments for construction in progress | 8,436,196 |
| Net cash provided by (used in) investing activities | 97,479,281 |
| Net proceeds from sale of common stock | 237,033,938 |
| Proceeds from exercise of stock awards and warrants | 11,858,358 |
| Net cash provided by financing activities | 248,892,296 |
| Net increase (decrease) in cash and cash equivalents | 276,560,316 |
| Cash and cash equivalents balance at beginning of period | 11,286,996 |
| Cash and cash equivalents balance at end of period | 287,847,312 |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)